Detailansicht

Wissensnetz

Person

Roman Hájek

Arzt

Name	Roman Hájek
Ort	Tschechische Republik
Akademischer Grad bzw. Titel	Prof. Dr.
Beruf	Arzt (charakteristischer Beruf)
Variante	R. Hájek
Beziehung	Ostravská univerzita
Datensatztyp	Person
GND-Nummer	1013763939
Datensatz-ID	1013763939
Beteiligt an alle anzeigen Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance Deciphering the genetics and mechanisms of predisposition to multiple myeloma Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Roman Hájek

Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance

Deciphering the genetics and mechanisms of predisposition to multiple myeloma

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives